TUMOR THERAPEUTIC VACCINES:
HOW CANCER VACCINES WORK

Tumor therapeutic vaccines are cancer immunotherapy treatments given to patients who already have cancer, not to prevent it. They stimulate the immune system to recognize tumor-specific antigens, mount a targeted T-cell response, and destroy cancer cells throughout the body.

“A therapeutic vaccine is like giving a soldier a new briefing while already in battle against an enemy that is hiding, changing its uniform, and actively fighting back.”

• Targeted Immune Activation

  Cancer cells evade immune detection by suppressing MHC expression and secreting PD-L1. Therapeutic vaccines present tumour-specific antigens in a highly immunogenic context, giving the immune system a precise 'wanted poster' for that specific cancer.

• T-Cell Priming & Memory

  Vaccines activate tumour-specific cytotoxic T-cells that expand, traffic to the tumour site, and can persist as memory cells — providing ongoing immune surveillance long after the initial vaccine course.

• Works Best in Combination

  Vaccines generate tumour-specific T-cells (the soldiers). Checkpoint inhibitors remove PD-L1/CTLA-4 suppression at the tumour site (remove the obstacles). Together, they are significantly more potent than either alone.

• Timing Is Critical

  Therapeutic vaccines work best when tumour burden is low — after surgery with no visible disease. Rapidly progressing disease may not allow time for the immune response (4–8 weeks to build) to take effect.

Confusing these two is the most common misunderstanding patients bring to consultations. They are biologically distinct challenges with fundamentally different mechanisms.

Six categories of therapeutic cancer vaccine exist, differing in what they deliver, how they are manufactured, and where they stand clinically.

• Personalised Neoantigen Vaccines

  The most ambitious category. Each patient's tumour is whole-exome sequenced, somatic mutations identified, and an algorithm selects neoantigens predicted to bind that patient's specific MHC molecules. The vaccine targets only proteins unique to that cancer — not found on normal tissue. Manufacturing takes 6–10 weeks. mRNA-4157/V940 (Moderna + Merck) is the most advanced clinical example.

• Shared Antigen Vaccines (TAA Vaccines)

  Target tumour-associated antigens (TAAs) overexpressed across many patients — PSA, PAP, MUC1, CEA, HER2, WT1. Scalable and off-the-shelf; no personalisation required. Risk: TAA expression on some normal tissues means autoimmune side-effects are possible. Sipuleucel-T (Provenge) is the landmark FDA-approved example — targets PAP in prostate cancer.

• Dendritic Cell Vaccines

  Dendritic cells — the immune system's professional antigen-presenting cells — are harvested from the patient, loaded ex vivo with tumour antigens (lysates, peptides, or RNA), and reinfused. Sipuleucel-T is technically a dendritic cell vaccine. Induces strong T-cell responses but is expensive and logistically complex to manufacture per-patient.

• mRNA Vaccines

  COVID-19 validated mRNA as a safe, rapidly manufacturable platform. The patient's cells translate the injected mRNA into tumour antigen protein, which is displayed on cell surfaces to trigger an immune response. mRNA-4157/V940 encodes up to 34 patient-specific neoantigens. Key advantage: once the computational neoantigen design is complete, the mRNA is synthesised in weeks.

• Viral Vector Vaccines

  A harmless virus (adenovirus, vaccinia, MVA) carries tumour antigen genes into cells near the injection site. The viral infection itself provides a strong immunogenic danger signal. Used in 'prime-boost' strategies: a first vector primes the response, a different vector boosts it — preventing anti-vector immunity from blunting the second dose. PROSTVAC (PSA-targeting) failed its Phase III despite promising Phase II data.

• Peptide & Whole Tumour Vaccines

  Peptide vaccines deliver short synthetic fragments of tumour proteins to prime T-cells against specific markers — used in melanoma, breast, lung, and pancreatic cancer trials. Whole tumour cell vaccines (e.g., GVAX) use irradiated tumour cells modified to secrete GM-CSF, attracting dendritic cells at the injection site to initiate a broad anti-tumour response.

Immunotherapy vaccines for tumor treatment have been found to be one of the best prospects in the treatment of cancers due to their precision-targeting nature, combined with sustained activation of the body's immune system. With the first US Food and Drug Administration-approved cancer vaccine having come into being back in 2010, the current trend involving personalized mRNA therapies capable of reducing chances of recurrence can show real results at last.

• 44%Reduction in Recurrence Risk — KEYNOTE-942mRNA-4157 + pembrolizumab vs. pembrolizumab alone in high-risk resected melanoma (HR 0.56).
• 79%2-Year Recurrence-Free Survival (mRNA-4157 Arm)vs. 62% in the pembrolizumab monotherapy arm in the KEYNOTE-942 Phase IIb trial.
• 6–10 weeksPersonalised Vaccine Manufacturing TimelineFrom tumour sequencing to first injection; limits use in rapidly progressing disease.
• 2010Year of First FDA-Approved Therapeutic Cancer VaccineSipuleucel-T (Provenge) for metastatic castration-resistant prostate cancer is a landmark proof of concept.
• 49%Reduction in Recurrence or DeathUpdated KEYNOTE-942 follow-up showed continued benefit for mRNA-4157 plus pembrolizumab versus pembrolizumab alone in high-risk resected melanoma.
• 4.1 moOverall Survival GainIn the IMPACT trial, sipuleucel-T improved median overall survival by about 4.1 months versus placebo in metastatic castration-resistant prostate cancer

The process of making a vaccine 'from your tumour' is not science fiction — it follows a defined computational and manufacturing workflow.

1. 1

   Tumour Biopsy & Normal DNA Collection

   A tumour sample (from surgery or biopsy) and a blood sample (normal DNA baseline) are collected. Both undergo whole exome sequencing — reading every protein-coding gene in the genome.

2. 2

   Somatic Mutation Identification

   Bioinformaticians compare tumour DNA to normal DNA. Every mutation unique to the cancer — called a somatic mutation — is identified. These are the raw candidates for neoantigen selection.

3. 3

   HLA Typing & Neoantigen Prediction

   The patient's HLA type (which determines the shape of MHC molecules that present peptides to T-cells) is identified. Algorithms trained on large datasets predict which somatic mutations will produce peptides that bind the patient's HLA and be visible to T-cells.

4. 4

   Vaccine Synthesis (mRNA or Peptides)

   Selected neoantigens are encoded into synthetic mRNA sequences (for mRNA vaccines) or synthesised as short peptide chains. For mRNA-4157, up to 34 neoantigens are encoded in a single lipid nanoparticle formulation.

5. 5

   Vaccine Administration & Immune Monitoring

   The personalised vaccine is administered — typically by injection, often with an adjuvant to boost immunogenicity. Concurrent checkpoint inhibitor therapy is standard in most trials. T-cell response monitoring confirms immune activation. Full immune response builds over 4–8 weeks.

Pivotal data from the most advanced therapeutic cancer vaccine trials.

Most therapeutic vaccines remain investigational. Sipuleucel-T is the only fully approved product. Active trial listings update frequently — CancerFax monitors these globally.

Patient selection is the most important determinant of therapeutic vaccine success. Picking the right patients at the right time is as critical as the vaccine itself.

The most important strategic shift in cancer vaccine science over the last five years is this: vaccines alone are rarely enough. The combination of vaccine + checkpoint inhibitor is now the dominant clinical paradigm.

• Vaccine = Creates the Army

  Therapeutic vaccines generate tumour-specific cytotoxic T-cells — soldiers that recognise and are primed to attack exactly that patient's cancer. Without the vaccine, these targeted soldiers don't exist in sufficient numbers.

• Checkpoint Inhibitor = Removes the Obstacles

  When vaccine-induced T-cells reach the tumour, they encounter PD-L1 and other suppressive signals that tell them to stand down. Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) block these signals — freeing the T-cells to fight.

• Turning Cold Tumours Hot

  Vaccines may convert immunologically "cold" tumours (few T-cells, no response to checkpoint inhibitors alone) into "hot" tumours full of primed T-cells — which checkpoint inhibitors can then amplify. This is one of the most important strategic insights in immuno-oncology.

• Key Trials Using This Strategy

  mRNA-4157 + pembrolizumab (KEYNOTE-942), autogene cevumeran + atezolizumab (pancreatic cancer), multiple neoantigen vaccines + nivolumab, ipilimumab, or atezolizumab across NSCLC, colorectal, and glioblastoma trials.

Three distinct pathways exist — only one involves a fully approved product. CancerFax adds most value in the clinical trial and compassionate use pathways.

1. 1

   Pathway 1: Approved Therapy (Sipuleucel-T)

   In the US, sipuleucel-T (Provenge) is FDA-approved for minimally symptomatic metastatic castration-resistant prostate cancer. The oncologist confirms eligibility, coordinates leukapheresis, and Dendreon manages the 3-infusion manufacturing and delivery cycle over one month.

2. 2

   Pathway 2: Clinical Trial (Investigational Vaccines)

   For all other cancer types and most patients globally, clinical trials are the primary access route. Eligibility requires confirmed diagnosis + current tumour tissue + biomarker testing (TMB, MSI, PD-L1, HLA). CancerFax cross-references your full clinical profile against open global trials and provides a prioritised matched list — including US, EU, and Israeli trial sites.

3. 3

   Pathway 3: Compassionate Use / Named Patient Programme

   For patients ineligible for trials due to geography or exclusion criteria, manufacturers occasionally grant compassionate use on a case-by-case basis with a strong clinical justification from the treating oncologist. More common in the US and EU. CancerFax can identify and assist with compassionate use applications.

Vaccine strategies require careful timing and sequencing decisions. This workflow helps patients avoid missed windows and wasted time.

1. 1

   Step 1: Full Biomarker Testing First

   Before discussing vaccines, obtain: TMB, MSI/MMR status, PD-L1 expression, and HLA typing (if a personalised vaccine is being considered). These results determine which vaccine strategies are biologically viable for your tumour.

2. 2

   Step 2: Standard of Care vs Investigational?

   Only sipuleucel-T is approved — for mCRPC. All other therapeutic vaccine strategies are investigational and accessed through trials. Know which category applies before planning your treatment pathway.

3. 3

   Step 3: Identify Open Vaccine Trials for Your Cancer Type

   Ask your oncologist specifically about neoantigen vaccine trials for your tumour. Many oncologists, especially outside academic centres, don't track every open trial. CancerFax's trial-matching provides a prioritised matched list with location and logistical information.

4. 4

   Step 4: Consider Timing Carefully

   Vaccine strategies are most effective after surgery when tumour burden is minimal — before the tumour creates a deeply immunosuppressive microenvironment. If you recently had a resection with clear margins, this may be the optimal window. Don't wait.

5. 5

   Step 5: Understand the Full Combination Strategy

   In virtually all active trials, vaccines are combined with a checkpoint inhibitor. Understand both components — the vaccine's manufacturing timeline, the checkpoint inhibitor's toxicity profile, and how they interact. Bridging therapy may be needed during the vaccine manufacturing phase.

6. 6

   Step 6: Consider International Trials if No Local Options Exist

   The most important personalised neoantigen vaccine trials are running in the US, Germany, and Israel. International enrollment is possible for eligible patients. CancerFax can identify international trial sites, assess geographic eligibility, and coordinate enrollment logistics.

Explore in-depth guides on every aspect of tumor therapeutic vaccines.

Frequently Asked Questions

The most common questions from patients and families exploring therapeutic cancer vaccines.